Education
About Us
Working with TipRanks
Follow Us
Arcellx, Inc. (ACLX)
NASDAQ:ACLX
ACLX Stock Chart & Stats
$66.00
-$3.36(-4.36%)
At close: 4:00 PM EST
$66.00
-$3.36(-4.36%)
Day’s Range― - ―
52-Week Range$47.86 - $94.07
Previous CloseN/A
Volume227.93K
Average Volume (3M)1.32M
Market Cap
$3.82B
Enterprise Value$4.24B
Total Cash (Recent Filing)$461.38M
Total Debt (Recent Filing)$51.79M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Feb 26, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding57,822,872
10 Day Avg. Volume1,192,621
30 Day Avg. Volume1,318,510
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)9.03
Price to Sales (P/S)38.06
P/FCF Ratio-42.39
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue118.01
Enterprise Value/Gross Profit5.23K
Enterprise Value/Ebitda-20.22
Forecast
1Y Price Target
$112.29Price Target Upside70.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-4.12
Revenue Forecast (FY)$32.67M
Bulls Say, Bears Say
Bulls Say
FDA Approval ProcessArcellx's anito-cel approval is well positioned under new FDA guidance for CAR T approval, which is expected to largely facilitate initial FDA approval.
Product LaunchA robust product launch for Arcellx's anito-cel is expected for late-line Multiple Myeloma patients.
Safety ProfileSafety remains a key differentiator for anito-cel, with no delayed neurotox reported and low rates of CRS and ICANS, which compare favorably to Cartitude-1 data of Carvykti.
Bears Say
Arcellx Inc News
ACLX FAQ
What was Arcellx, Inc.’s price range in the past 12 months?
Arcellx, Inc. lowest stock price was $47.86 and its highest was $94.07 in the past 12 months.
What is Arcellx, Inc.’s market cap?
Arcellx, Inc.’s market cap is $3.82B.
When is Arcellx, Inc.’s upcoming earnings report date?
Arcellx, Inc.’s upcoming earnings report date is Feb 26, 2026 which is in 61 days.
How were Arcellx, Inc.’s earnings last quarter?
Arcellx, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.983 by -$0.007.
Is Arcellx, Inc. overvalued?
According to Wall Street analysts Arcellx, Inc.’s price is currently Undervalued.
Does Arcellx, Inc. pay dividends?
Arcellx, Inc. does not currently pay dividends.
What is Arcellx, Inc.’s EPS estimate?
Arcellx, Inc.’s EPS estimate is -1.06.
How many shares outstanding does Arcellx, Inc. have?
Arcellx, Inc. has 57,822,872 shares outstanding.
What happened to Arcellx, Inc.’s price movement after its last earnings report?
Arcellx, Inc. reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.983. Following the earnings report the stock price went up 0.788%.
Which hedge fund is a major shareholder of Arcellx, Inc.?
Currently, no hedge funds are holding shares in ACLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcellx Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.29 (70.14% Upside)
$112.29 (70.14% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.92%
12-Months-Change
Fundamentals
Return on Equity
-47.18%
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Company Description
Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Stock 12 Month Forecast
Average Price Target
$112.29
▲(70.14% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---